CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 14, 2006--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced that it has been awarded the James D. Watson Helix award for corporate excellence in the 'emerging/mid-cap' category. The award was announced today at the 8th Annual BIO CEO & Investor Conference in New York. The Helix award, the biotechnology industry's sole award for outstanding corporate achievement, honors biotechnology companies that display leadership in three distinct areas: product development, economic growth, and corporate citizenship.
